Tim is a lead statistician at Peter Mac, Assistant Professor at the department of Clinical Neuroscience at the Karolinska Institute in Sweden, Head of Statistics at the MSBase Registry and senior statistician at the Burnet Institutes. He is also a practising medical doctor with particular interests in epidemiology, population and public health.
- Population and public health
- Real World Evidence
- Data registries & data linkage
- Clinical trials
- Health Economics
- Evidence evaluation for regulatory and reimbursement settings
Assistant Professor Tim Spelman is a PhD biostatistician and clinician with over 20 years of experience in statistics and epidemiology. He is currently Head of Statistics of the MSBase international multiple sclerosis clinical outcomes registry at Monash University, senior statistician at the Department of Clinical Neuroscience, Karolinska Institute in Sweden and has also has current positions with both the Burnet Institute and the Department of Surgery St Vincent’s Hospital in Melbourne. He has also served as the advising statistician to the Economics Sub-Committee of PBAC since 2014 and a consultant statistician to the Lancet since 2014. He has authored or co-authored over 200 publications in infectious diseases, virology, epidemiology, public health, health economics, immunology, health technology assessment and neurology. His statistical fields of interest include clinical trials, particularly pragmatic and adaptive trials including the application of Bayesian methodologies, real world analysis of registry-based and other big datasets, data linkage, evidence evaluation in health technology assessment and health economics. Dr Spelman has previously worked for Peter Doherty Institute for Infection and Immunology, the Victorian Infectious Diseases Service, VICNISS Healthcare Associated Infection Surveillance System, the United Nations Programme on HIV/AIDS, Monash University’s Department of Epidemiology and Preventive Medicine. He also has considerable clinical trial experience, serving in both trial statistician and Data & Safety Monitoring Committee capacities in many clinical trials, both locally and internationally. Dr Spelman previously spent 10 years at the Australian Bureau of Statistics working on population census and health economics data. He also has a strong international reputation. In addition to his work on population registries and data linkage at the Karolinska Institute, he has recently collaborated with Righospitalet in Copenhagen analysing disease registries and has further worked as both a statistician and clinician in Southern Africa with Medecins sans Frontieres. He has further served on clinical trial advisory boards and scientific leadership groups for pharmaceutical companies including Biogen, Novartis and Roche.